Beiersdorf Receives Approval for Thiamidol in China

By Nina Kienle

Nivea maker Beiersdorf received approval to commercialize in China its treatment Thiamidol, which is used to reduce skin pigmentation.

The Hamburg-based company said Tuesday that China's National Medical Products Administration approved its hyperpigmentation treatment, the first active ingredient receiving approval since the introduction of the Chinese Cosmetics Regulation.

Thiamidol was launched on the market in 2018 and rolled out globally in 2019. Since 2021, it has been available to Chinese consumers via cross-border e-commerce, Beiersdorf said.

The product launch on the Chinese market is expected in the next 12 to 18 months.

Hyperpigmentation is a common, usually harmless condition in which patches of skin are darker than the surrounding skin.

Write to Nina Kienle at [e-mail]

(END) Dow Jones Newswires

11-05-24 0557ET